Brewin Dolphin's Q3 2021: Quarterly Review

Strong growth in profits provided a boost to company shares during the third quarter of 2021, but anxiety over the future tempered those gains. In their recent report, Criticaleye Advisory Member, Brewin Dolphin, looks back at the events that have shaped markets over the past three months and highlight what to expect in 2022. 
 
Key takeaways include:
  • Some of the supply shortages can be blamed on companies that misjudged what lockdown would mean, in terms of goods demand.
  • ‘Upstream’ oil prices have been rising but, towards the end of the quarter, oil availability became an even greater problem ‘downstream’, as a shortage of HGV drivers made it difficult to get petrol to filling stations.
  • Going into 2022, it seems likely that monetary policy will tighten.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
The Road to Renewables

Thomas Thune Andersen, former Chair of Ørsted, reflects on a decade of transformative leadership. He talks to Criticaleye’s Emily Jones about steering the Danish company’s business model from fossil f...

Click here to download this insight
Harnessing Real-time Data as ...

Paul Sheriff has successfully combined high level financial and operational leadership at several growth businesses since 2008. In this interview with Criticaleye’s Jacob Ambrose Willson, he discusses the nature o...

Click here to download this insight
Change Reinvented

In today's business landscape, continuous change is the new reality and navigating it effectively is essential to activating strategy and moving organisations forward. In this research, Criticaleye Partner, Accen...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 2,104




LDC Tullow Oil plc AlixPartners Eightfold AI Bunzl plc Veolia Water Technologies Eton Bridge Partners Redwood Bank London Stock Exchange Concentrix Google Legal & General Investment Management NATS Amazon UK Experian Drax Group plc Salesforce GlaxoSmithKline plc Royal London Group Workday Lightsource bp Accenture Mayborn Group E.ON UK Robert Walters